Skip to main content
. 2022 Mar 8;13:787884. doi: 10.3389/fgene.2022.787884

TABLE 1.

The characteristics of ccRCC patients included in this study.

Variable Overall cohorts (n = 507) Training cohorts (n = 243) Testing cohorts (n = 264) ICGC cohorts (n = 89)
Age (year, Mean ± SD) 60.26 ± 12.08 60.21 ± 12.46 60.31 ± 11.72 60.48 ± 10.06
Gender (n, %) Male 333 (65.7) 163 (67.1) 170 (64.4) 50 (56.2)
Female 174 (34.3) 80 (32.9) 94 (35.6) 39 (43.8)
Stage (n, %) Stage I 253 (49.9) 116 (47.7) 137 (51.9) 0 (0.0)
Stage II 53 (10.5) 28 (11.5) 25 (9.5) 0 (0.0)
Stage III 116 (22.9) 59 (24.3) 57 (21.6) 0 (0.0)
Stage IV 82 (16.2) 39 (16.0) 43 (16.3) 0 (0.0)
Unknown 3 (0.5) 1 (0.5) 2 (0.7) 89 (100.0)
T stage (n, %) T1 259 (51.1) 119 (49.0) 140 (53.0) 51 (57.3)
T2 65 (12.8) 34 (14.0) 31 (11.7) 9 (10.2)
T3 172 (33.9) 84 (34.6) 88 (33.3) 27 (30.3)
T4 11 (2.2) 6 (2.4) 5 (2.0) 2 (2.2)
N stage (n, %) N0 225 (44.4) 90 (37.0) 135 (51.1) 40 (44.9)
N1 16 (3.2) 10 (4.1) 6 (2.3) 0
NX 266 (52.4) 143 (58.9) 123 (46.6) 49 (55.1)
M stage (n, %) M0 401 (79.1) 198 (81.5) 203 (76.9) 35 (39.3)
M1 78 (15.4) 38 (15.6) 40 (15.2) 4 (4.5)
MX 26 (5.1) 7 (2.9) 19 (7.2) 50 (56.2)
Unknown 2 (0.4) 0 (0.0) 2 (0.7) 0 (0.0)
Survival status (n, %) Alive 162 (34.0) 77 (31.7) 85 (32.2) 60 (67.4)
Dead 345 (66.0) 166 (68.3) 179 (67.8) 29 (32.6)
Survival years (Mean ± SD) 3.25 ± 2.18 3.00 ± 2.03 3.48 ± 2.29 4.17 ± 1.69

SD, standard deviation.